KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) EPS (Weighted Average and Diluted) (2020 - 2025)

Aquestive Therapeutics (AQST) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.27 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 42.11% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$0.78, down 52.94%, while the annual FY2025 figure was -$0.78, 52.94% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.27 in Q4 2025 per AQST's latest filing, down from -$0.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.11 in Q1 2023 and bottomed at -$0.73 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.22, with a median of -$0.2 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 134.38% in 2023, then tumbled 550.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.73 in 2021, then soared by 71.23% to -$0.21 in 2022, then surged by 38.1% to -$0.13 in 2023, then plummeted by 46.15% to -$0.19 in 2024, then crashed by 42.11% to -$0.27 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.27 in Q4 2025, -$0.14 in Q3 2025, and -$0.13 in Q2 2025.